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Inguinal hernia repair (IHR) is the most common general surgical procedure in the United Kingdom, with an estimated 80 000 cases a year. The past decade has seen an increase in the use of prosthetic mesh in open and laparoscopic hernia repair based on the premise of a tension-free repair. 1 Conversely, although traditional repair with suturing using the Shouldice technique has been reported with low rates of recurrence, it is difficult to learn and often associated with high rates of recurrence when done in the wider community. Recent reports have indicated that laparoscopic repair is associated with less immediate postoperative pain and a faster return to normal activities, particularly for recurrent and bilateral hernias. 2 Large case series indicate recurrence rates for open and laparoscopic mesh repairs as low as 0.2%, 3 and randomised trials of open primary IHR, with follow up as short as two years, have consistently found fewer recurrences associated with using mesh than not, 2 4 with similar results reported for recurrent hernias. 5 We examined these changing trends in IHR in southeastern Scotland between 1985 and 2001.
Participants, methods, and results
We retrospectively identified all patients undergoing IHR between January 1985 and January 2002 in six surgical centres in southeastern Scotland using the Lothian surgical audit database (available in all these hospitals for some or all of this period), hospital coding systems (OPCS3 and OPCS4), and data from the Information and Statistics Division of the Public Health Institute of Scotland. Population data were taken from the UK census and the General Register Office for Scotland. Poisson and logistic regression were used to analyse the data.
Overall figure) .
Laparoscopic mesh IHR was first introduced to southeastern Scotland in 1993, and its use in primary repair increased to 18% (186/1027) by 1996, then remained static. For recurrent hernias, however, use continued to rise to 42% (41/98) by 2001. Up to this time no surgeon had done prophylactic contralateral IHR in the region.
In this period, the total number of primary repairs increased significantly at an average annual rate of 1.25% (P < 0.001), while the population within southeastern Scotland remained static at about 745 000 residents between 1985 and 1991, and increased by an average 0.49% a year from 1992 to 2001. The annual number of recurrent repairs did not change significantly, but the annual rate of recurrent repairs decreased significantly as a proportion of the total, from 11.7% to 8.8% (P < 0.001). The median patient age at time of surgery did not change significantly over the study period; Spearman's rank correlation r s = − 0.09, P = 0.72 (primary repairs) and r s = 0.35, P = 0.16 (recurrent repairs).
Comment
The annual ratio of recurrent to primary repairs has significantly decreased in southeastern Scotland, during a period in which surgical technique has changed while selection criteria have remained the same. This ratio started falling before the introduction of mesh repair, indicating that other variables may be involved. Although changes in recurrence rates may lag up to 10 years behind changes in surgical technique, 40% occur 1996 1997 1998 1999 2000 2001 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 Inguinal 
Sibutramine may be associated with memory impairment
David W J Clark, Mira Harrison-Woolrych Sibutramine (Reductil, Abbott), a serotonin and noradrenaline reuptake inhibitor is widely used in the management of obesity. The Intensive Medicines Monitoring Programme in New Zealand has received a report of amnesia in a 39 year old woman taking sibutramine 10 mg daily. Memory impairment became evident one month after starting sibutramine and progressively worsened until her daily activities were severely affected. She also experienced increased frequency of migraines associated with neck stiffness. Within two weeks of stopping sibutramine her amnesia improved, and it had resolved completely by six weeks. Another case has been reported to the Australian Adverse Drug Reactions Advisory Committee. A 50 year old woman experienced amnesia, headache, and insomnia one day after starting sibutramine 10 mg daily, with the symptoms resolving four days after discontinuation. The World Health Organization's international database contains 33 further reports of amnesia associated with sibutramine. In 25 cases, sibutramine was the only drug suspected of causing the amnesia. Onset of amnesia was within four days of sibutramine administration in 13 cases and between 5 and 30 days after administration in four cases. Ten patients were reported to have recovered after stopping sibutramine. Three patients with amnesia associated with sibutramine were also reported to have experienced a cerebrovascular event, and one of these was reported with concurrent hypertension. Seven other patients experienced symptoms possibly associated with cerebrovascular insufficiency, including confusion, dizziness, dysarthria, and abnormal vision.
Memory impairment might be part of a cerebrovascular syndrome, but sibutramine may contribute directly to amnesia. Serotonergic pathways play important roles in learning and memory, and antagonists of several 5-HT receptors prevent memory impairment.
1 Drugs such as sibutramine that increase synaptic serotonin concentrations may thus contribute to memory impairment. Other serotonin reuptake inhibitors have been reported to be associated with memory loss. 2 3 Although amnesia is listed as a reported event during postmarking surveillance of sibutramine in the US product information, 3 our literature searches found no published reports of this adverse event.
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